Resveratrol inhibits glioma cell growth via targeting oncogenic microRNAs and multiple signaling pathways

GUANGXIU WANG1-3*, FANG DAI4*, KAI YU5, ZHIFAN JIA1-3, ANLING ZHANG1-3, QIANG HUANG2,3-5, CHUNSHENG KANG1-3, HAO JIANG6 and PEIYU PU1-3,5

1Laboratory of Neuro-Oncology, Tianjin Neurological Institute; 2Key Laboratory of Post-trauma Neuro-repair and Regeneration in Central Nervous System, Ministry of Education; 3Tianjin Key Laboratory of Injuries, Variations and Regeneration of Nervous System, 4State Key Laboratory of Applied Organic Chemistry, Lanzhou University, Lanzhou, Gansu 730000; 5Department of Neurosurgery, Tianjin Medical University General Hospital, Tianjin 300052, P.R. China; 6Department of Neurology, Henry Ford hospital, Detroit, MI 48202, USA

Received November 12, 2014; Accepted December 29, 2014

DOI: 10.3892/ijo.2015.2863

Abstract. Resveratrol (Res), a natural polyphenolic compound, has anticancer activity in a variety of cancers. In the present study, the antitumor effect and underlying molecular mechanism of Res on rat C6 glioma growth was studied. The results demonstrated that Res inhibited glioma cell proliferation, arrested cell cycle in S phase and induced apoptosis in vitro. Res also suppressed intracranial C6 tumor growth in vivo and prolonged survival in a fraction of the rats bearing intracranial gliomas. Res significantly downregulated the specific miRs, including miR-21, miR-30a-5p and miR-19, which have been identified as oncomiRs in our previous studies, and altered the expression of their targeting and crucial genes for glioma formation and progression such as p53, PTEN, EGFR, STAT3, COX-2, NF-κB and PI3K/AKT/mTOR pathway. Therefore, the anti-glioma effect of Res, at least in part, is through the regulation of oncogenic miRNAs. The effect of Res on non-coding RNAs should be studied further. Res is a potential multi-targeting drug for the treatment of gliomas.

Introduction

Malignant gliomas are the most common and highly aggressive primary brain tumors. Even using multiple modalities of treatment, including maximal safe resection, radiotherapy, and chemotherapy, the prognosis of patients with malignant gliomas remains dismal (1,2). Therefore, novel therapeutic strategies and drugs for treatment of malignant gliomas are urgently required.

A large number of chemopreventive and chemotherapeutic agents have been discovered from natural products and provided promising approaches to treat and prevent cancer (3,4). Res (3,5,4’-trihydroxy-trans-stilbene), a naturally polyphenolic compound, has been identified in the skin of red grapes, peanuts and various food products. It has a variety of important biological effects such as suppression of platelet aggregation, anti-inflammatory, anti-oxidant, and vasorelaxant activities (5-7). Res also exhibits antitumor properties by blocking the three stages of carcinogenesis, initiation, promotion and progression (8). Res has exerted anticancer effects against prostate, breast, leukemia and other epithelial cancer cells. There are some reports on the studies of the treatment of gliomas with Res (9-12) but the molecular mechanism of its antitumorigenic or chemopreventive activities is complex and not fully understood.

The objective of the present study was to investigate the anti-proliferative effect of Res on glioma cells using both in vitro and in vivo models. It is well known that small non-coding regulatory RNAs - microRNAs (miRs) are found to be dysregulated in almost all types of cancers and play important roles in cancer development and progression (13-17). Recent studies have demonstrated that miRs can be regulated by natural agents such as curcumin and Res resulting in suppression of tumor growth, drug resistance and metastasis (18-21). Our previous studies have confirmed that specific miRs, including miR-21, miR19 and miR-30a-5p are upregulated in GBMs with significant oncogenic activity and their major targeted genes involved in gliomagenesis (22-24). Antisense oligonucleotides of these miRs significantly suppress the glioma cell growth either in vitro or in vivo (25,26). We examined the alteration of these specific miRs in GBM cells after treatment with Res, and also the expression of their targeted genes and the genes related to glioma formation and progression.

Materials and methods

Cell culture. Rat C6 glioma cells were obtained from the Institute of Biochemistry and Cell Biology, Chinese Academy...
of Sciences. Cells were cultured at 37°C with 5% CO₂ in Dulbecco's modified Eagle's medium (Invitrogen, USA) supplemented with 10% heat-inactivated fetal calf serum, 4 mM glutamine, 50 U/ml penicillin and 50 µg/ml streptomycin (Invitrogen). Cells were subcultured every other day.

**Cell proliferation examined by MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide) assay.** MTT were purchased from Sigma-Aldrich (St. Louis, MO, USA). Cells were implanted in 96-well plates (4,000 cells/well) and allowed to grow overnight, then treated with 50, 100 and 150 µM of Res or 0.3% DMSO for 24, 48, 72 and 96 h, and exposed to 20 µl MTT (5 mg/ml) at each time-point, then incubated for additional 4 h. The resulting formazan crystals were solubilized with DMSO and optical density was measured in triplicate wells at the wavelength of 570 nm. Results were expressed as percentage of control.

**Cell cycle kinetic analysis.** C6 glioma cells (6x10⁵ cells/well) were plated in 10-cm dishes and incubated for 24 h. DMSO (0.3%) or different concentration of Res (50, 100 and 150 µM) were added to the dishes and incubated for additional 48 h. Cells were trypsinized, washed with PBS, fixed with 70% ethanol for a minimum of 30 min, and incubated with RNase A (100 µg/ml) for 30 min at 37°C. Cells were then stained with propidium iodide in PBS (50 µg/ml) for 30 min at room temperature. Samples were analyzed by FACSCalibur flow cytometer and Modifit software (Becton-Dickinson, USA).

**Detection of apoptotic cell death.** The extent of apoptotic cell death was analyzed by using Annexin V-FITC Apoptosis Detection kit (BD Biosciences, USA). Cells (6x10⁵ cells/dish) were cultured in 10-cm dishes for 24 h, treated with 0.3% DMSO and 50-150 µM of Res for 48 h. Then both adherent and floating cells were harvested, double-labeled with Annexin V-PE and 7-amino-actinomycin, examined with FACSCalibur flow cytometer and analyzed by CellQuest software (Becton-Dickinson, USA).

**Western blot analysis.** Total proteins were extracted from cells treated with 0.3% DMSO or 50, 100 and 150 µM of Res for 48 h. The protein concentration was determined by Lowry method. Protein (40 µg) was subjected to SDS-PAGE. Separated proteins were transferred to PVDF membranes (Millipore, USA), followed by incubation for 1 h in blocking buffer. The membranes were then incubated separately with primary antibodies against EGFR, PI3K, p-AKT, mTOR, PTEN, VEGF, PCNA, Cyclin A, cyclin E, Bcl-2, Caspase-3, GFAP, NF-κB, Stat3, COX-2 (1:500 dilution, Santa Cruz Biotech, USA), followed by incubation with HRP-conjugated secondary antibodies (1:500 dilution, Zymed, USA). The specific proteins were detected using a SuperSignal protein detection kit (Pierce, USA). After washing with stripping buffer, the membranes were reprobed with an antibody against β-actin (1:500 dilution, Santa Cruz) following the procedures described above. The relative quantification was expressed as the density of specific proteins divided by the density of β-actin.

**Immunohistochemical staining.** After Res treatment, cells were immunostained for MMP-9 or NF-κB by ABC-peroxidase method. Briefly, cells grown on the coverslips for 24 h were treated with DMSO (0.3%) or Res (100 µM) for 48 h, then fixed with 4% paraformaldehyde, treated with 3% hydrogen peroxide and incubated with appropriate antibodies (1:1,000 dilution, Santa Cruz) overnight at 4°C. After incubation, biotinylated secondary antibody (1:1,000 dilution, Zymed, USA) was added and incubated for 1 h at room temperature, followed by incubation with ABC-peroxidase for additional 1 h. Then washing with Tris-buffer, the cells were incubated with DAB (3,3′-diaminobenzidine, 30 mg dissolved in 100 ml Tris-buffer containing 0.03% hydrogen peroxide) for 5 min, rinsed in water and counterstained with hematoxylin.

**Tumor growth in vivo.** Rat models bearing intracranial C6 glioma were established as described previously (25). All
animal experiments were approved by the Animal Care and Use Committee of Tianjin Medical University (Tianjin, China). Rats were randomly divided into two groups: control (10 rats) and treated (8 rats). In treated group, rats were given Res 8 mg/kg/day by oral administration until the end of observation period. The general behavior and survival of the rats were observed. The tumor growth in each group of rats were monitored at regular intervals using high-resolution MRI in order to compare the tumor volume at different periods in each individual animal. Whenever the rats in the control or Res treated group died naturally or were sacrificed at various time-points, their brains were removed and prepared as paraffin-embedded sections for histopathological examination and immunohistochemical staining. The expression of EGFR, GFAP, PCNA, MMP-9, NF-κB, COX-2 and VEGF was detected by immunohistochemistry. The primary antibodies (1:1,000 dilution, Santa Cruz) used and the procedures were the same as described above.

Statistical analysis. The results are expressed as mean ± SD. A Student's t-test was used to compare individual data with control value. A probability of p<0.05 was considered to be significantly different from control data.

Results

Res inhibits glioma cell growth. The survival rate of C6 glioma cells treated with Res was measured by MTT assay. As shown in Fig. 1, the suppressive effect of Res on the proliferation of C6 cells was dose- and time-dependent. After treatment with 150 µM Res for 24 and 96 h, the survival rate of C6 glioma cells declined to 58±1.26 and 19±1.52%, respectively, as compared to the control.

Res arrests the cell cycle. The effect of Res on cell cycle kinetics was analyzed by flow cytometry. The data obtained from cells treated with 0.3% DMSO and 50, 100 and 150 µM of Res for 48 h are summarized in Fig. 2. Two-to-three fold increase of S phase fraction was demonstrated in C6 cells treated with different concentration of Res as compared to the control. These results suggested that Res was able to delay the cell cycle progression and inhibited the cell proliferation by arresting the cells cycle at S phase.

Res induces apoptotic cell death. The effect of Res on the apoptosis of glioma cells was determined by Annexin V-PE immunofluorescence staining. Apoptosis in glioma cells treated with Res was induced and the population of apoptotic cells was significantly increased in a dose-dependent manner. The percentage of apoptotic cells increased from 2.50 to 11.06% in C6 cells treated with 50-150 µM of Res (Fig. 3).

Res downregulates the expression of miR-21, miR-30a-5p, miR-19 and their targeted or related components. qRT-PCR and the comparative Ct (ΔΔCt) method were used to determine the change of miR-21, miR-19 and miR30a-5p expression in C6 glioma cells before and after treatment with different concentration of Res. It was found that the expression of all these miRs was significantly downregulated in Res treated cells and also in a dose-dependent manner (Fig. 4).
Western blot analysis demonstrated that the expression of EGFR, PI3K, p-AKT, mTOR, VEGF, PCNA, Bcl-2, NF-κB, STAT3, COX-2 was downregulated, whereas the expression of p53, PTEN, Cyclin A, cyclin E, GFAP and Caspase-3 was upregulated in glioma cells treated with 50, 100 and 150 µM of Res (Fig. 5). In addition, MMP-9 and NF-κB expression were decreased as shown by immunohistochemical staining (Fig. 6).

**Antitumor effect of Res in rat C6 glioma xenograft.** *In vivo* experiment showed that the general condition of rats was deteriorated at one week after injection of parental C6 glioma cells. The mean survival time of rats in control group was 15.80±0.93 days (10 rats died on days 12, 13, 14, 15, 16, 17, 18, 19 and 21, respectively). Eight rats receiving Res treatment had a longer survival than the control rats, with a mean survival of 29.75±9.27 days (8 rats died on days 13, 14, 15, 17, 21, 25, 43 and 90, respectively). There was a statistical difference between the mean survival time of the treatment group and the control group (p<0.05) (Fig. 7).

Two out of eight rats treated with Res had more favorable response. Their general conditions returned to normal at ~4 weeks after treatment. In one of them the primary tumor focus disappeared on day 73 and in another longer survival rat the tumor disappeared on day 35 as shown by MRI (the rats were sacrificed on days 90 and 43, respectively). Histopathological examination of their brains showed no macroscopic gliomas but only a tiny amounts of tumor cell residue in the original tumor region (Fig. 8). These results indicated that Res could inhibit tumor growth and prolong the survival in a fraction of the rats bearing intracranial C6 gliomas.

Besides, there were no apoptotic cells found in the tumor specimens of control rats. However, increased number of apoptotic cells could be observed in the tumors of Res-treated rats as detected by TUNEL method (Fig. 9).

The immunohistochemical staining of rat brain tumors treated with Res also demonstrated that the expression of EGFR, MMP-9 NF-κB, PCNA, COX-2 and VEGF was decreased, whereas the expression of GFAP was increased as compared with those in control rats (Fig. 9). These results suggested that multiple signaling molecules might be modulated by Res.

**Discussion**

The present study investigated anti-glioma effect of Res and its underlying molecular mechanism. Our results demonstrate that Res exerts a significant inhibitory effect on C6 glioma cell growth in a dose- and time-dependent manner. This anti-
proliferative effect appears to result from the cell cycle arrest at S-phase and induction of apoptotic cell death. These results are in accordance with the findings from previously reported studies (27-29). Limited information is available on the anti-glioma effect of Res in vivo. In this study, we found that the survival of a fraction of rats bearing intracranial gliomas treated with Res is prolonged. Among them, two rats had more favorable response to Res. These results indicate that Res is able to inhibit glioma growth both in vitro and in vivo, which is similar to the study of the suppressive effect of Res on the tumor growth of RT-2 glioma in vitro and in vivo (11). In addition, Gao et al reported that Res has strong anti-proliferative and pro-apoptotic effects against 32Dp210 leukemic cells in vitro, but Res at doses of 8 mg/kg/day and 40 mg/kg/day (oral administration for 5 days/week throughout the experiment) is ineffective in slowing down the progression of leukemia, as the doses escalated to 80 mg/kg/day, Res can prevent a small fraction of mice from leukemia-induced death (7). Based on our previous experiments on the rat C6 glioma models, the intracranial C6 gliomas shown by MRI could not regress spontaneously without appropriate treatment. It is conceivable to suggest that Res could inhibit tumor growth in a fraction of rat C6 gliomas. However, the dose of Res we used for the treatment of xenografts in vivo is low, whether the escalated doses of Res will enhance the suppression of glioma growth should be further studied.

Res has been shown to have antioxidant, anti-inflammatory, cell cycle arrest and cell death-inducing properties. Therefore, it is predictable that multiple targets and complex molecular events may be involved in Res-mediated inhibition of glioma cell growth.

Alterations of a number of miRNAs play an oncogenic or tumor suppressor role in glioma formation and progression. Our previous studies have shown that miR-21, miR-19 and miR-30a-5p are overexpressed in gliomas and glioma cell lines, and involved in gliomagenesis as oncogenic miRs through their targeting genes. Antisense oligonucleotides of these miRs significantly suppress the glioma cell growth either in vitro or in vivo. The first study of Res affecting endogenous miRNAs was conducted in a human colon cancer cell line, Res was identified to decrease the levels of oncogenic miRNAs, including miR-17, -21, -23a/b, -146a and -103-1/2, and increase the level of tumor suppressor miR-663 (30). We also found that Res is able to inhibit the expression of oncogenic miR-21, miR-19 and miR-30a-5p in glioma cells.

MiR-21 overexpression in gliomas and glioma cell lines is a general consensus. It has been identified as a predominant microRNA altered in gliomas and play a crucial role in a myriad of biological processes. To our current knowledge, miR-21 targets sets of genes associated with tumor suppressive and pro-apoptotic function, such as PTEN, p53, TGF-β, PDCD4, TPM1 and Reck (31-34). MiR-21 expression is also correlated with downstream factors such as Bcl-2 and MMP2, which may represent indirect targets affected by the expression levels of miR-21, since there is no evidence of direct interaction between miR-21 and 3'UTR of their mRNA.

The expression and function of miR-19 and miR-30a-5p in gliomas have not been reported before. However, PTEN, the target of miR-19 we identified in glioma cells (23), and also reported as the target of miR19a/b in gastric cancer
Besides, miR-30 family members have been found to regulate cell apoptosis through the p53-Drp1 (dynamin-related protein 1) pathway.

PTEN is the common target of miR-21 and miR-19 and the critical tumor suppressor in GBM (24). As shown in Fig. 6, Res suppresses miR-21 and miR-19 may induce PTEN activation and results in repression of the major oncogenic PI3K/AKT/mTOR signaling pathway in glioma cells, leading towards inhibition of tumor cell proliferation, invasion and induction of apoptosis. p53 is also the major target of miR-21, and tumor suppressor p53 deletion and mutation is also an important molecular event in gliomas. As shown in the present study, we demonstrated that p53 expression is significantly upregulated after treatment with Res. So that Res suppresses glioma cell growth, at least in part, through downregulation of miR-21 and miR-19 and consequently, upregulating PTEN and p53.

EGFR overexpression is one of the most important genetic aberrations in malignant gliomas. A number of studies have demonstrated that EGFR is overexpressed in 60-90% of glioblastomas (36), as well as in C6 glioma cells (25). Hyperactivated EGFR signaling promotes cell growth and inhibits apoptosis via its major downstream and crosstalk signaling pathways, such as PI3K/AKT/mTOR and RAS/MAPK, which can regulate cell survival, proliferation, invasion and angiogenesis (37-39). Our previous studies have demonstrated that antisense and dominant-negative EGFR cDNA or siRNA targeting EGFR effectively inhibit glioma cell growth (25,40). It has also been found that there is a significant correlation between EGFR and miR-21 levels in glioma cells. Antisense miR-21 markedly reduced EGFR expression in our previous study (24). Thus, the overexpression of EGFR is decreased in C6 glioma cells after treatment with Res, may be partially through the inhibition of miR-21.

Figure 8. The MR images of intracranial C6 gliomas in the rats treated with Res (8 mg/kg/day) survived for 43 and 90 days, respectively.
STAT3 overactivation is associated with a variety of cancers, including gliomas, and is identified as a master regulator of biological processes leading to the cancer formation (41-43). The present study demonstrates that Res significantly represses the expression of STAT3. This is one of the major reversions of aberrant molecular events in glioma cells following treatment with Res. It has been reported that Res suppresses constitutively active STAT3 in all the NK cell lines by inhibiting JAK2 phosphorylation but not other upstream mediators of STAT3 activation.

We have found previously that STAT3 binds to the miR-21 promoter by CHIP analysis and the STAT3 inhibitor significantly reduced miR-21 expression (44). Thus, STAT3 activation suppressed by Res may contribute to the reduced expression of miR-21.

The anti-inflammatory property of Res results from its inhibitory effect on the synthesis of pro-inflammatory mediator COX-2, and downregulation of COX-2 is also mediated by the inhibitory effects of Res on the important nuclear transcription factor NF-κB. COX-2 overexpression has been documented in malignant gliomas and strongly correlated with the poor prognosis of glioblastomas (45). COX-2 catalyzes the conversion of free arachidonic acid to prostaglandins. Prostaglandins can stimulate tumor cell proliferation, promote angiogenesis, and suppress apoptosis. Res significantly inhibits the expression of COX2 and NF-κB either in vitro or in vivo. The suppres-

Figure 9. The expression of EGFR, PCNA, NF-κB, GFAP, COX-2, VEGF and MMP9 detected with immunohistochemical staining and the apoptotic cells determined by TUNEL method in rat intracranial C6 glioma untreated and treated with Res.
sive effect of Res on COX-2 is also suggested as one of the molecular mechanisms responsible for its antiglioma activity. Additionally, NF-κB is constitutively activated in a number of cancers, including gliomas, Res can downregulate the expression of NF-κB-regulated genes, including Bcl-2, VEGF, and MMP-9, through which it may also affect apoptosis and invasion of glioma cells. Banerjee et al showed that Res inhibits the activation of NF-κB in breast cancer cells and dietary administration of Res in rats bearing mammary tumors inhibits tumor growth and decreases the expression of NF-κB, COX-2 and MMP-9 in tumor tissues (46). It is consistent with our findings that the expression of NF-κB, COX-2, MMP-9 and VEGF is decreased in glioma cells after Res treatment.

Recently, it has been reported that Res can downregulate lncRNA (long non-coding RNA) MALAT-1 that results in the inhibition of Wnt/β-catenin signaling pathway and suppression of human colorectal cancer cell invasion and metastasis (47), whereas Wnt/β-catenin signaling pathway is also an important oncogenic pathway to promote glioma cell growth as we reported before (48). Thus the effect of Res on non-coding RNAs should be studied in more detail.

In addition, the preclinical studies have shown that Res enhances the antiglioma effect of temozolomide (TMZ) via ROS-dependent AMPK-TSC-mTOR signaling pathway and inhibiting autophagy, or Res reverses TMZ resistance via downregulation of MGMT. It has also been reported that Res sensitizes GBM tumor initiating cells to radiotherapy by inhibition of STAT3 axis (49-52).

Taken together, the results from the present study demonstrate that Res could inhibit cellular proliferation and potentiate apoptosis in rat C6 glioma cells both in vitro and in vivo. Based on the interfering with the expression of several oncogenic miRs and a panel of genes of signaling pathways involved in the processes of gliomagenesis and possibly sensitizing chemos- and radiotherapy for gliomas after treatment with Res, it is conceivable that Res could be classified as a multi-targeting agent.

Since Res is able to cross the blood-brain barrier and incorporate into brain tissue, and its toxicity is minimal even high doses used long-term in rats and mice (3,5,3). Therefore, clinical trials in human gliomas are urgently required. Currently, analogs of Res with improved bioviability are being developed as potential anticancer agents, and clinical trials of Res against some other cancers are being conducted (54,55). It is expected that Res will provide at least an adjuvant for currently available combined therapy against malignant gliomas.

Acknowledgements

This study was supported by the Natural Science Foundation of China (no.81101915).

References


